ZIMMER BIOMET HOLDINGS INC shares fell 7% Tuesday after the medical device maker maintained its 1% to 3% revenue growth forecast for 2026. The cautious outlook follows a United States sales force overhaul that caused the loss of two large customer accounts this quarter. Investors are weighing a $0.10 raise in profit guidance against execution risks as the company restructures its commercial model.

Sales Force Overhaul Drags on Growth